M3 Wealth Management LLC Acquires Shares of 3,842 Astrazeneca Plc $AZN

M3 Wealth Management LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,842 shares of the company’s stock, valued at approximately $674,000.

Other institutional investors have also added to or reduced their stakes in the company. Cibc World Market Inc. lifted its holdings in Astrazeneca by 21.5% during the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after purchasing an additional 11,398 shares during the last quarter. TD Asset Management Inc lifted its holdings in Astrazeneca by 20.0% during the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after purchasing an additional 181,273 shares during the last quarter. AMG National Trust Bank lifted its holdings in Astrazeneca by 20.4% during the third quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after purchasing an additional 7,289 shares during the last quarter. Assetmark Inc. lifted its holdings in Astrazeneca by 6.5% during the third quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock valued at $23,813,000 after purchasing an additional 19,020 shares during the last quarter. Finally, US Bancorp DE lifted its holdings in Astrazeneca by 6.6% during the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after purchasing an additional 15,065 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Trading Up 0.0%

Shares of Astrazeneca stock opened at $187.10 on Wednesday. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a market cap of $290.18 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 1.59 and a beta of 0.26. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company’s 50-day moving average price is $191.50 and its 200-day moving average price is $183.36.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities analysts expect that Astrazeneca Plc will post 9.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on AZN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Citigroup assumed coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Finally, DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.